RBC Positive on Sarepta Therapeutics (SRPT) Into Tomorrow's R&D Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
Go back to RBC Positive on Sarepta Therapeutics (SRPT) Into Tomorrow's R&D Day
June 20, 2018 8:38 AM EDT
Goldman Sachs raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $203.00 (from $127.00) while maintaining a Buy rating following the company's R&D day. SRPT reported highly encouraging preliminary Ph1/2 NCH micro-dystrophin gene therapy data from cohort B for the three initially-dosed patients... More
June 20, 2018 7:16 AM EDT
BTIG raised its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $170.00 (from $120.00) while maintaining a Buy rating. Analyst Timothy Chiang continues to see SRPT as a disruptor in the Duchenne Muscular Dystrophy treatment market with its pipeline of gene therapy and RNA-splicing product... More
June 19, 2018 10:42 AM EDT
Baird analyst Brian Skorney calls Sarepta Therapeutics (NASDAQ: SRPT) DMD gene therapy results "really positive."
Skorneycommented, "The initial results, in two patients, are beyond encouraging. We think this data could indicate levels of expression that could be functionally converting patients from a... More
June 19, 2018 10:21 AM EDT
Preliminary Phase 1/2a of Sarepta Therapeutics' (NASDAQ: SRPT) gene therapy for DMD showed an average of 38% of micro-dystrophin compared to normal utilizing its method of measurement. Analysts expectations were for a 10%-15% gain, according to Bloomberg.
...
More
